COMP <GO>
INVA vs PAHC // OPERATING MARGIN
Innoviva Inc. (NASDAQ) VS. Phibro Animal Health Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: INVA 5
— PAHC 5
▲ OPERATING MARGIN LEADER: INVA
LAST: $21.31 (+0.90%) • MKT CAP: $1.54B
operating-margins
39.80%
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
operating-margins
8.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INVA VS. PAHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INVA | PAHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.80% | 30.90% | +43.90 | INVA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | 9.90% | +4.80 | INVA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.6x | 19.2x | -11.60 | INVA | /valuation <GO> |
| Free Cash Flow Yield | 12.72% | 5.08% | +7.64 | INVA | /fcf-yield <GO> |
| Operating Margin ACTIVE | 39.80% | 8.50% | +31.30 | INVA | /operating-margins <GO> |
| Net Profit Margin | — | 3.70% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 14.70% | 27.40% | -12.70 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.23% | -1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.87 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.4 | 56.9 | -3.50 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.54B | $1.58B | -$38.2M | PAHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INVA REV | PAHC REV | INVA GROSS % | PAHC GROSS % | INVA FCF | PAHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $411.3M | $1.30B | 74.8% | 30.9% | $195.8M | $80.1M |
| FY 2024 | $358.7M | $1.02B | 82.6% | 30.8% | $188.4M | $87.6M |
| FY 2023 | $310.5M | $977.9M | — | — | $141.1M | $13.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INVA // BETA —
PAHC // BETA —